




The  
Patent  
Office

PCT/GB97/00074

The Patent Office  
Cardiff Road  
Newport  
Gwent  
NP9 1RH



I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation and Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

PRIORITY DOCUMENT

Signed

Dated

28 JAN 1997





# Patents Form 1/77

(k. 1977)

The  
Patent  
Office

15JAN86 E167095-10 000335  
F01/7700 25.00

£25.00

## Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference

JDM/DCS/P93928GB

2. Patent application number

(The Patent Office will fill in this part,

**9600470.0**

10 JAN 1996

3. Full name, address and postcode of the or of each applicant (underline all surnames)

THE UNIVERSITY OF LIVERPOOL  
SENATE HOUSE  
ABERCROMBY SQUARE  
P.O. BOX 147  
LIVERPOOL, L69 3BX  
ENGLAND

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

ENGLAND

891184004

B

4. Title of the invention

METASTASIS INDUCING DNA'S

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

W.P. THOMPSON & CO.,  
COOPERS BUILDING  
CHURCH STREET  
LIVERPOOL L1 3AB

Patents ADP number (if you know it)

0000158001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

YES

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

# Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 17

Claim(s)

Abstract

Drawing(s) 6

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date 10/1/96

12. Name and daytime telephone number of person to contact in the United Kingdom

D.C. SCHILLER  
0151 709 3961

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

-1-  
DESCRIPTION

METASTASIS INDUCING DNA'S

The present invention relates to metastasis inducing DNA's, a method of identifying such DNA's, and their use in diagnosis and therapy.

Most cancers are thought to be due to alterations in specific genes caused either by mutation making their gene-product in some way more effective or by overexpression of a normal gene giving an enhanced effect. These oncogenes have largely been identified by introducing gene-length fragments of DNA from human cancers into a mouse fibroblast cell line, in culture, and selecting those cell lines that grow in an uncontrolled manner in liquid or semi-solid medium. The oncogenes themselves have been isolated by cloning the human DNA fragments away from the mouse DNA by standard recombinatorial techniques. Alternatively mutations can arise in genes that suppress their own activity such as, for example, p53 or Rb or which suppress the levels of their products such as, for example NM-23. These are referred to as tumour suppressor oncogenes. In the commonly-occurring cancers, it is believed that between 5 and 7 such changes in oncogenes or tumour suppressor oncogenes are required to produce a full-blown cancer.

The major forms of cancer, including breast

cancer, lung cancer and colonic cancer cannot be cured effectively because, although the current therapies may be effective against the primary tumours, they are largely ineffective against the disseminating or metastasizing cells, which ultimately kill the patient. Despite the enormous effort in cancer research very little is known at the molecular level about the most important life-threatening process, that of metastasis. Most of the oncogenes and suppressor oncogenes that have been discovered have been found from their ability to promote uncontrolled growth of the mouse fibroblast cell line. The major problem in this field is that determining cell growth does not give a measure of the process of metastasis. In fact, although uncontrolled growth is an important aspect of the initial events in the development of a cancer, the rate of growth of distant metastases can be remarkably slow. Hence the process of metastasis is largely independent of processes involving cell-growth, except in its final phases. Therefore, it is unlikely that oncogenes and tumour suppressor oncogenes will have much involvement in the process of metastasis and be useful diagnostic or therapeutic targets for control and elimination of metastatic disease.

It is one object of the present invention to

identify DNA comprising, consisting of or containing sequences involved in metastasis, hereinafter referred to as metastasis inducing DNA's or Met-DNA's for short.

According to a first aspect of the present invention there is provided a method of screening and recovering Met-DNA comprising the steps of:

1. transferring fragments of human DNA from malignant, metastatic cancer cells into a cell line that produces only benign, nonmetastasizing tumours when injected into syngeneic animals;
  2. injecting the transformed cells into a syngeneic animal;
  3. selecting those animals in which metastasizing tumours have been identified; and
  4. recovering the Met-DNA therefrom.
- Preferably the DNA fragments transferred in step 1 are fragments of from 0.5 to 50k base-pairs.

Preferably the cell line that produces only benign non-metastasizing tumours when injected into syngeneic animals is a rat mammary epithelial cell line, such as, for example Rama 37.

Preferably the fragments of human DNA from malignant, metastatic cancer cells are tagged to assist in their removal or insertion from or into a host or vector, such as, for example, the

oligonucleotide tag illustrated in Fig. 1. This tagging procedure overcomes the problem of identifying the inserted human DNA sequences in the rat genome of the transfected rat cells. Human-specific repetitive DNA (Alu) sequences are spaced sufficiently in the human genome that in many human DNA fragments of this size they will be absent.

In one embodiment, fragments of human DNA from malignant, metastatic breast cancer cells are introduced into a rat mammary epithelial cell line Rama 37 which produces only benign, nonmetastasizing tumours when injected into syngeneic rats.

By way of example only, the transfer of restriction-enzyme HindIII-fragmented DNA from malignant metastatic rat and human breast cancer cell lines into a benign Rama 37 cell line produced a small proportion (1-3%) of transformants which, when reintroduced into the syngeneic rats, caused these cells to metastasise, principally to the local lymph nodes and lungs. In contrast, fragmented DNA from nonmetastatic cells and the standard oncogenes (Ha-ras, Middle T Antigen gene, and Large T Antigen gene) produced no metastasizing transformants. The latter result confirms the non involvement of such oncogenes in the metastatic process per se. However, the fact that metastasis can be transferred in a genetically



dominant manner suggests that other dominantly-acting DNA fragments are largely responsible for this process. The full results of the above experiments are shown in table 1, which shows the incidence of tumours and metastases for Rama 37 transfected cell lines.

The column headed cells injected give the cell type in short hand, and full details are given below:

Rama 37 are Rat mammary 37 benign cells; R37-Ca2-LT1 is a cell line from a lung metastasis of Rama 37 cells transfected with fragmented DNA from the metastatic breast carcinoma cell line Ca2-83 (Cancer Res 54 2785-2795, 1994); B-T1 is a cell line from a primary tumour of Rama 37 cells transfected with fragmented DNA from the benign breast cell line HMT-3522 (Cancer Res. 54 2785-2795, 1994); R37-Ca2-HT is a cell line of Rama 37 cells transfected with tagged DNA fragments from metastatic transformant R37-Ca2-LT1; R37-Ca2-H is a cell line of Rama 37 cells transfected with untagged DNA fragments from metastatic transformant R37-Ca2-LT1; R37-B-HT is a cell line of Rama 37 cells transfected with tagged DNA fragments from the benign transformant B-T1 as a control; R37-F1 is a cell line of Rama 37 transfected with PCR fragment F1 from a cell line of a lung metastasis of R37-Ca2-HT; and R37-F2 is a cell line of Rama 37

transfected with PCR fragment F2 from the same cell line of a lung metastasis of R37-Ca2-HT.

The b annotation in the column headed metastases identifies the transfecting DNA's giving rise to significantly more metastasis than Rama 37 cells ( $P < 0.05$ , Fisher exact test). The animals were autopsied after 3 months.

To aid the rescue of metastasis-inducing human DNA sequences from the rat transformant cell lines, all the HindIII-fragmented DNA's from one such metastatic transformant, R37-Ca2-LT1 (Table 1) were tagged at both ends with double-stranded synthetic oligonucleotides that provide restriction enzyme and unique PCR primer sites. These are shown in Fig. 1. The tagged DNA fragments include 4 restriction sites: SfiI and NotI, a defective HindIII site at the 3' end for linking to the HindIII sites at the ends of the human DNA fragments, thereby destroying it, and an internal HindIII site located near to the 5' end, which when cut after ligation generated new fragments with HindIII ends. The fragments were transfected into the parental Rama 37 cells, and after transfer of the cells to the mammary glands of syngeneic rats, metastatic cell lines were isolated from the resultant rat lung metastases. The tagged, fragmented DNA incorporated into the metastatic transfected Rama 37

cell lines was directly amplified between the tags by PCR and yielded bands at about 1300 to 1500 bp that were responsible for the metastasizing ability of the transfected cells. These results are shown in Fig. 2 which shows the DNA fragments produced by PCR of metastatic transformants. Two new cell lines, established from the culture of lung metastases of R37-Ca2-HT (tagged, metastatic DNA transformant) and R37-Ca2-H (untagged, metastatic DNA transformant) (see Table 1) in rats were termed HTLu and HLu, respectively. They were run against the tagged benign transformant cell line R37-B-HT and the tagged metastatic transformant R37-Ca2HT. Cellular DNA was amplified by PCR using a short oligonucleotide primer of 22 bp from positions 3-24 of the tag sequence as shown in Fig. 1. Compared with the control DNA's from HLu and B-HT cells, two extra bands, F1 and F2, of about 1300 bp and 1500 bp respectively, were specifically amplified from genomic DNA of the Ca2-HT and HTLu cells when PCR'd DNA samples were run on 0.8% agarose gels containing ethidium bromide and photographed in U.V. light. The fluorescent bands of DNA are shown in negative imaging for clarity. Cloning of these pooled DNA's yielded six independent fragments and the results are illustrated in Fig. 3. Fig. 3 shows pBluescript clones of metastatic DNA

fragments F1 plus F2. The two broad PCR DNA fragments F1 and F2 were excised from the gel in Fig. 2, combined, and cloned directly using the AT procedure into a suitably modified pBluescript vector and the clones of recombinant vectors (C10,C9 etc) were cut with HindIII to excise the cloned fragments. These cut recombinant vectors were analysed on a 0.8% agarose gel containing ethidium bromide and photographed in U.V. light. The sequences of clone C10 and C9-DNA's were identical; vec = vector DNA and ins = insert DNA corresponding to the cloned DNA of about 1000 bp. Transfection of these cloned DNA fragments singly into the parental benign cell line confirmed that all fragments (C2,C5,C6,C9,C12 and C20-DNA's) produce metastases. These are shown in Table 2 which tabulates the incidence of tumours and metastases for Rama 37 cells transfected with cloned Met-DNA's. The superscript a & b indicate:

<sup>a</sup>Nomenclature: pSV2neo, benign Rama 37 cells transfected with the selection vector for the cloned DNA fragments alone; C2-DNA, benign Rama 37 cells transfected with the vector and the insert from clone 2 of the pBluescript library of the F1 and F2 pooled DNA's, and similarly C5 to C20 -DNA.

<sup>b</sup> indicates significantly more metastases than vector transfected Rama 37 alone ( $P < 0.05$ , Fisher exact

test). Animals were autopsied after 3 months.

Thus Koch's postulate has been satisfied for all metastasis-inducing-DNA's (Met-DNA's) in this system.

Southern hybridisations and PCR amplifications have established that the Met-DNA's are specifically present in their respective transformants.

Fig. 4 shows detection of C9-DNA in transformant cell lines. Cellular DNA was isolated from (A) a cell line from a lung metastasis produced by injection of C9-DNA transfected Rama 37 cells in rats; (B) C9-DNA transfected Rama 37 cells (see Fig. 3 and Table 2); (C) benign Rama 37 cells; (D) benign BT-1 cells (see Table 1). These DNA's were digested with HindIII and the digested DNA was analysed on 0.8% agarose gels either by (A) Southern blotting to a probe of [<sup>32</sup>P] radioactively labelled C9-DNA, and the radioactivity visualised on X-ray film or (B) by PCR using the 17 oligonucleotide fragment from either end of the C9-DNA as primers and run with a standard molecular weight marker ladder. The newly synthesised DNA in B is visualised by fluorescence of the ethidium bromide in the gel in U.V. light. Surprisingly, the sequences of these Met-DNA's illustrated in Figs. 5 to 10, although human in origin, do not correspond to known genes and most do not include any obvious open reading frames. Furthermore none of these Met-DNA's

are expressed as mRNAs in their transformants and hence are not dominantly-acting oncogenes. They therefore contain entirely novel short stretches of regulatory DNA capable of inducing metastasis.

According to a second aspect of the present invention there are provided DNA comprising, consisting of or containing the metastasis inducing DNA from the sequence:

C2

```
CTTCCTTGGT GCTCTATGTC TTGCCTCTCC CTTTCTCCAG TCCCATTAAG CCATAACCAT
CTTGACAGAC TCTGGGACAG TCCCCTCTGC TCTCCTGTTG GCGCCTGAGT CCCTTTTTCG
CTGAGGACCC TTCACGTAGC CTCCCATCTG GATGACCTAG TAGAAGACGT GGGAAGTTGT
CACACTCAGG TAACTGAGCA GAGCTCAGAG ATTTAAAGTG AGTCTGGGGA GCCTCGAGGA
TTGATCTGCT GCCTTAAAAA GCCAATTGGA TGAATAACCC AGACTATTGT CACTTTAGGT
GGGAAGTCAC TAGCATATCT GATGGGTCAC ATCTGAGAAA GGTTCCTAGC AGTGGTGGCC
TTGTGTGAGC AGCATGGCGT GTATCATGGT GTGCAGCATA CTCAGGCTGC TTGCAACACT
CGAGGCTCTT CTTCAGTATT AGGGGAACCA CTGGTGTTSG AACATGGTCC AAGAATACAG
TCATGTGAGG AGAATCCCAA TGCGTCAGGA GAAAACGAGA GTCTGTGACC TCCATTCTTC
AAGATACAGA ATTATTCTTG GACTGTGTTT TCATGCTCCT TGTGGATGGG AGTGAGTTTA
CTTCAGGTTA ATCAGCATTG CTTACTGTTG GTATTCAAGT AAATGCTTAA ATTATCCTGG
ATATACCTCT GTGGGAAGCA GGTTTTTGAT ACATGCAGCT TGTCTTGTG ATTGATACTG
CTTGAAGTCA AGAGAACTTT GCTCATGTGA TCTTTCTTAA CCGATGGAGT AGAACTGTC
TGATGCTCTC AATAAAGTTG GCTCTGTCAC GAGACGTTAG TCTGTCCTGT TTATCTGCTC
CATTCTTCCG CTCCCACGGC CTCTACAGCA CTAAACCCAC CACCGATAGA CTCAGTCTTT
CACTGACAAA CATCACCAGA GGCTCTTAAC TGAGATTATA AACTGTTACT AGATGATGGG
TGGAATCGCT CCCCAGAAAC ATAAACATTT ACTTGAGAA CTCAAGACCC CTTTGTAGAC
ATAACTCCCA TGGT
```

According to a third aspect of the present invention there are provided DNA comprising, consisting of or containing a metastasis inducing DNA from the sequence:

C5

ATTGCTGTGA	GCCTATTAGC	GACATTTGGT	GACGCCCTT	TTAAGGGGGT	AGATACAAAG
AATGGGTTGA	AATTCTGTGC	CACAAACGCT	CTCCATGTTT	TCACAATTAC	ACTTGCAACC
TGTGGTCAGC	AGCCAGAATT	TAGGGATGTG	ATGGGACAGG	GTCGGGGAAA	GAAGGAGAAG
GGTAAAGGAA	AGACAGCAGC	TTAAAGTCCA	AACAGCTCCA	GGAGACTATC	TGTAGAAATA
ACATCAGACC	ATGAGGAGAA	TTGATATCAT	TGTTTTTCAA	TGGGTATCGC	CAAGGGAACT
TTCCATCTGA	TTAAAAATAA	TTACTGCTGG	CACTAAATCC	AATTGGAAAT	GCCCCACACA
ATTTATCTTC	CAC TTCATGC	TGCTACCATA	TGCCTGACGT	GGCGGAGCAG	AAGCATTCCC
TCCCGTTCTG	ATAAATAGTA	CTTTGTAAAT	ATTTGGAGAC	GGGAGCTCTG	GTGACAGGGA
ACACGTACAA	ACCGGCCTGT	TTATCATGTT	CCCGATAGAG	GGCCTCTTTG	ACGTACAGGA
CCCCAAAACA	GTCAGGATGC	TGTGAATTTT	CTTCCATGAA	GCCTTGTTCA	CAATTAGCAA
CCATTGGAGG	AAGCAGGCTG	CACTGTCTAC	CACAAGTGGC	ACTTTCCAAA	GAGCACACAT
ATATTGGAGC	AAGACATTTT	GCTGGCTGAC	TGGTGCTGTG	TAAGCTGATA	AACTGCTATA
TTTATTAAAC	TGGCTTTTCT	TTGAACACCC	CACCAAGGA	AAAAAAAACA	CACCTAGGGT
GACATTATTT	GGAGATGAAG	TCTTTATAGA	GATGCTTAAG	TTTAAACGAG	ACTTTTAAAG
CCGGCTCTAT	TCCATTTAAT	GAATGGTGTG	CCTACAAAGG	AAGAACTGG	GACAGAGGTA
TGTACACTTG	TGTGTGTGTG	AGAGACAACG	TGAGGAGCTG	AAGAGGAGCA	CGTACAAGTC
AGAGAAAGGC	TGACCCTTAT	TCACACTGAG	CAAACCACTC	ATGTGTGGGT	CGATAGATGA
GAGTATCCCC	CAAGACTCAC	ACATTCCAAC	GCTTGGTC		

According to a fourth aspect of the present invention there are provided DNA comprising, consisting of or containing a metastasis inducing DNA from the sequence:

C6

AGGACCAGAG	TTCACATCCC	ATCAAATGGC	CCAGAAGGTT	TTAATGCTGT	CTTTTGGCCC
AGGGGCGAAC	TGCACACACA	TGTGCACATA	CACTTACAGA	GACACACATT	CAGCAGCATA
AGAACACAAT	CACAAATAAA	AAAAATCTTG	AAAAATTTTA	AGCTAAAATT	GTAAAGAAAT
AACATATATA	CAATTTTCT	TTATTTTTTT	AAAGATTTAT	TTATTTAATG	TATATGAGTA
CACTGCCTCT	CCCTCCAGAC	ATAGCAGTAC	AGGGCATCGG	ATCCCATTAC	AGATGGTTGT
GAGCCACCAT	GTGGTTTCAC	AGATGGTTGT	GAGCCACCAT	GTGGTTTCAG	GAATTGAACT
CAGGACCTTT	GGAAGAGCAG	TCAGTGCTCT	TAACCTCTAA	GCCATCTCTC	CTGACCCTTA
TATACAATTT	TAATGCTACG	TACACACAAC	TTCTCTTTCC	TTTAATGGTT	GAGATTTTGT
TCTGGAGAAG	TAAGAATAAA	GGAGGGAAAG	AACATTGCTT	TCACATTGCA	CCAGTGGGAA
CAGCGTGTGT	AAAGTAGGAA	TGCCATGAAA	TGACTGGCCT	GCCTTCTCAT	TACTGTTCCT
CCCACTCCTC	CTTTTAACTG	GAGCTCCTTT	ATCTAATTTA	TTAGTTTGAC	GATACCCAGG
GTTTTCTTCT	GTTTTGATCT	TTTTAAGACA	GAGACTCACC	ATATAGCCCT	GGCTGGCCTG
AAGCTCACTA	TGTAGACCAG	TCTGGCCTTG	AACTCAAAGG	AGATCTATCT	GCTTCCTAGT
GCTGGGATTA	AAGGCTTGTG	CTACCAAGTC	TGGTCTGAGG	CTTTGGAGCA	GCCTCGGTTT
TGGCCTTCTT	TAAGGATCTC	TAAGCTAGCA	GTAAGTAGCC	TAGCCATGCT	GTTGTAGGAA
GTTGTTGCTT	CATCCTGGCT	CCAGCACAAA	GGCAGTCACT	AAACGTCGGC	CTCATTTTCT
CAGAGCTGAA	TGCAAATTCC	TTGTGCTCTT	CCTGTGTCCT	CCTGGAAC	

According to a fifth aspect of the present invention there are provided DNA comprising, consisting of or containing a metastasis inducing DNA from the sequence:

C9

AGTTGGGGAC ACAGCTTGCT TGATTAAGAT GTTCTTGGG AAAAGGAGTT AAGCCTAATG  
ATTTCCAATG GAAAGGACTG CTAATTGGGG AGGCAATGTT GCTTAATTGG GACACCTGCG  
GGTAATTAAA AGCTCTCTCC CAGTGGCCTT TCCTGTTTTT GGCTCTGGGA GGCGAAGGCA  
TTGAGAGGGA TGCAGGCATT CTAAGGGCTG GTTCTTGTTT TCTCCCTTCC CCTCTGTCCA  
AACTCAGTGA GGTATCCCTG TCTGTGCTGT CCTTAGAGTG CCGTCCTGAG GCCTTGTTG  
GTTAAGGTCT CTGGATCTGA GCTGCCTCAG GGAAACGCAT GAGCTCATTG GAAAGGGGAG  
AACCAGGCAA AGGTGTTGGC TGTGACCTCA GAATTCTGAG GGGCAAAGGT TCAAGGCTAA  
CTCTCATTAT AGAGCAAGTT TGAGACTGGC CTGGGAACAA AAATATAAAG TGAGTGAGGT  
CATATGACAG CACCTGAGGA GTCCTGTCCC TAGAGATCAT AAGGACCTGG CTGCTGGGGA  
CTTGTTGCAG ATGGCACTTT GTGTCGAGAG AGGGGACCTG CCCCAGCATG GGAGGCCCTG  
GAAGATCCTC TGGATTAAC GTGAACACTG ATTGCTGCTT TATACCTGGA GTTGTGCTGT  
TATCTGGTAC ACATCTGCTG GGTGAATGAG TTCATGGGCT TTATTTTCACT GAGGTATTTA  
CCTGAGGAGA AAGAAGGACT GGTGCCACAA AGCACAGCTT TTAAATCTGT GGGTTGTGAC  
CCATTATGGA CTATCATAAC TGAGTGCAGG TATCAAGAAT ACTTTAGCAG GTGGTAAAAA  
GATTTTTGAA TGCGCAACGA CCAAACTGA ACTCAAAAAT CAAGCATGGC ATGGATCCTG  
GGTGCTCCTG GAAGCACTTG CCTTTACTGC ATTGTGCGAC TTGACGGTAG CCTTGGTTCT  
GAATGCACAA CACGTGGGCT TTGGGCTGCA CAGGCCACCA CGCCGTGCCT GAAACACCTC  
AGCTCAGGTT TGTGGCTATG TCCTATGACT TGGACTTACT TTTATTGCAC ATATAAATAT  
TTTCCTGC



According to a sixth aspect of the present invention there are provided DNA comprising, consisting of or containing a metastasis inducing DNA from the sequence:

C12

GAGGGGGTGG	TGGCACAGTT	ATGTTTTTGT	AGGAAGGGTT	CCATGAACCT	CAGCAGAGCT
CGGGTTAGAA	ATTTAAAAGC	CCTGAGGGGA	ATTTTTTTTT	TAAATCGCTA	TGAATCTGAC
ATGAGAAAAA	CAGATCAGAA	ACGTTCTTGT	GCTTCAGAAA	AGGACAAGTG	TGTGAGCTAA
CAGACTGCAC	ACTGGTGTTT	GAGGCACATC	TGGATCACAG	GAGCGTCAGA	TAATGTCCCC
AAAGGTAAAT	GCATTTGCTT	GCACAGTACC	GAGTGTGGTG	GGGGGTGCCT	ACAGCCCAGC
GGTTCTCAAC	CTTCCTGATG	CTTCGACCCT	TTAATACAGT	GCCTCATGCT	CTGGTGACCT
CCCCAACCTT	AAAATTATTT	TTGTTGCTGT	TCATAACTGT	GATTTTGATA	CTGTTATGAA
TTGTAATATA	AATAATTTTG	AAGAAAGAGG	TTTGCCAAGG	GTTTGAGAAC	TGCTGTTCTA
GCCCCACGTG	GATGGTTTTT	CGTCATTTGG	GGTTTTTATG	AGGCAGAGTC	TTATGTAGCC
CAGGCTAGCA	GCCTAGAATG	TGCTACTTAG	CTGAGGAATA	ACCTTGGAAC	TTCTGAGGAC
TGGAGAGACT	GGCTTAGTCC	TCAAGAAACT	GGAAATAGCT	GGAGTTTGGC	TACTTGTGGG
TTCTTTTTTC	TTCAAACCTT	TTCTACTCTT	TTTCCACCCT	GTCGGCCCCC	TAACACTAAA
TAAGAAAGAG	AAAGGGGAGC	ATAGAGGGGA	AAAGAAACCC	CTGAATAACG	TCAGTAGTTG
GCAAAGGGGG	GTGACATATG	TTGTCATTAG	ACCACATCCT	GGTGATTAAG	GGGAGTCAAG
TTCTTTGGGG	CAAGTTTGAT	CTTTCGTGTA	ACGATATCTA	ATTTCTTCTC	CCTGTTGCTT
CGTCTTTGTG	AACAACGACT	TGATAACCCA	CAATGGACCA	TCAACCAACC	AACCAACCAT

According to a seventh aspect of the present invention there are provided DNA comprising, consisting of or containing a metastasis inducing DNA from the sequence:

C20

```

TTGTCTCTGG TGTTACTTGT TTTCCCATTT CTGACAGTGG TTTGACCTT CTATACGCCT
GTGTGTCAGG AGTGCTGTAG ACCTATTTTC CTGTTTTTCTT TCAGCCAGTT ACAGGAACAG
AGTGTTCTAC TGTCAGATGT GTAGCTGTTC CTGTCCACTG ACTTTCAAGC TGTCTCTGTG
TGCAGGAACC AGAAGGGCCT GTCCCTACTT CTACTGGGCC CCTACGCACA GGGGGCCTAG
ATGGTGCTAG GTGTTTTCCCT CTAGAGCCTG AAATGTGGGC AGAGAGTAGT CTCCTCTGGT
TTCCTAGGTA TGTCTTCCCC TCTGAAGGTC TAGCTCTCCC TTCCATGGGA TATGGGTGCA
GGGAGCTGTT TGACCAGGTC CTCTCAAATC CGGGTGCAGT CTGGACCGCA GGCTCCTGTA
GCTTGCCTGC TGCAATCTTC CCGCACCCAG AGGCACCCAA GTTTCCTCTT GGGCCAAGGA
TGTGGGCAAA GGTGGGCAGA AGTGGCAATC TCTCCTGCCC TAGCGTCTCA GGATTGCCCT
CACTTCTGGG CAATCCGCTC TCTCTTCCAC AGGGTTTGGG AGCAGGGAGC TGTGGGCCGG
TATCAGGCAA AGGTTTGAGG CAACCAGTTA GAAACTGGAA GTGTCAGGTC CCAGAGGAAT
TTTGCCTTTG TGTGTCCTGA GTCCACCAGG CAGGTCACCT GGAGCAGAAA AATTGGTTTT
CCCCTCGGTC TCAGGCCTGA AGTGCACCT CAGGGTTGGC TTTGAGCTGT ACCTGTGGAA
AGTATGGTTT TAAAAATCTA AGATAGCTAT CATGCAGCAA GGCTTGTGTA AAATGTCTAT
TTGGTTCCTT TATGACTTAC TTTTGCTGTA CTGAGGATCA AACCTAGGGT CTCAAGCAGT
CATCACAATT CTCTGTCACT GATCCAGCTC CATTCTATT TTCTTTTGT CCGCGCGATC
TCTCGCCAGC AAGAAAACAC GCTAGGGACA TACGAATCCT TGCTGCAGCC AAAACTTTTA
TTGAATCTTA AGGAGAAGCC CGCGACCCG ACTGGCGCGG TTTATATACA CCCTAGCACA
GTGCATCCAC A

```

According to an eighth aspect of the present invention there is provided a method of detecting metastasis inducing or inhibiting genes by screening for differences between the messenger RNA expressed between Met-DNA - transfected and nontransfected cells.

In one embodiment Met-DNA's, are introduced into a benign rat mammary epithelial cell line Rama 37.

By way of example and to help identify the regulatory function that short stretches of human malignant DNA (precursor to Met-DNA's) may exert on the transfected Rama 37 cells, the mRNA expression of the metastatic transformant rat mammary cell line R37-Ca2-LT1 was compared with its benign parental cell line Rama 37 using subtractive hybridisation techniques. Of the four subtracted clones three corresponded to known rat genes for proteins including osteopontin and one corresponded to a novel rat gene of unknown function. As an example only, transfection of rat osteopontin cDNA into the parental Rama 37 cells produced transformants that induced a high frequency of metastasis compared with vector controls confirming the metastatic capability of the osteopontin gene.

These overall results have established a causal relationship between the Met-DNA's and metastasis on the one hand and the over-or underexpression of certain rat genes, at least one of which is novel, that are linked to the metastatic process in this rat system. Controls with DNA's from nonmalignant, nonmetastatic sources as well as the oncogenes Ha-ras-1, Polyoma Large T Antigen and Polyoma Middle T Antigen failed to induce metastasis establishing the specificity of the inductive processes in this system.

At present the most useful indication of whether a breast or other common cancer will metastasise in the future in a patient is whether the primary tumour has already spread to the local lymph nodes. This test only works on a population basis. For example, in breast cancer, there are many examples of patients with no tumour in the lymph nodes at presentation who later die of metastatic disease and of patients with metastatic deposits in the lymph nodes who live a normal life-span. Thus an accurate test of good predictive value for the occurrence of metastases would be important in selecting those patients for vigorous conventional chemotherapeutic treatments without causing the potentially harmful side-effects in those patients who do not need this treatment.

According to a ninth aspect of the present invention there is provided a probe specific to a DNA comprising, consisting of or containing a metastasis inducing DNA or gene or fragment thereof according to the invention.

By specific is meant hybridises to any target DNA under suitable salt and temperature conditions to allow detection of identical or related DNA molecules.

Preferably the probe is provided as part of a kit which may additionally comprise one or more of the following: a colour indicator; an oligonucleotide

primer; materials for gel analysis, and/or materials for DNA transfer or hybridisation.

The Met-DNA sequences may be detected in tumour or biopsy specimens by standard Southern blotting, PCR-based or in-situ techniques to identify those patients at risk from metastatic disease. Physical methods of detection based on imaging techniques may also be possible. Expression of metastasis - inducing genes may be detected by standard mRNA hybridisation PCR amplification or by antibodies specific for the gene-product.

According to a tenth aspect of the present invention there is provided medicaments adapted to target DNA comprising, consisting of or containing a metastasis inducing DNA or gene or fragment thereof of the invention.

In one embodiment such Met-DNA's, metastasis-inducing genes or fragments thereof, could be targeted in the cancer cells to excise or block their function using synthetic oligonucleotides based on a knowledge of the sequence of the Met-DNA's, metastasis-inducing genes or fragments thereof, of the invention.

In another embodiment such Met-DNA's, metastasis-inducing genes or fragments thereof, may be targeted for treatment using standard antibody and antisense mRNA/ribozyme techniques for detection and for destruction, respectively.



Table 1

Donor DNA	Cells injected*	No. rats	Tumours	%	Metastasis	%
None	Rama 37	46	22	48%	0	0%
Human metastatic	R37-Ca2-LT1	20	18	90%	6 <sup>b</sup>	33%
Human benign	B-T1	18	18	100%	0	0%
Human/rat metastatic tagged	R37-Ca2-HT	37	29	78%	6 <sup>b</sup>	21%
Human/rat metastatic	R37-Ca2-H	31	24	77%	4 <sup>b</sup>	17%
Human/rat benign tagged	R37-B-HT	39	31	79%	0	0%
PCR fragment F1	R37-F1	30	28	93%	12 <sup>b</sup>	43%
PCR fragment F2	R37-F2	40	36	90%	9 <sup>b</sup>	25%





Table 2

Transfecting DNA <sup>a</sup>	No. rats	Tumours	%	Metastasis	%
pSV2 <sup>neo</sup>	26	13	50%	0	0%
C2-DNA	18	18	100%	6 <sup>b</sup>	33%
C5-DNA	25	25	100%	3	12%
C6-DNA	18	18	100%	9 <sup>b</sup>	50%
C9-DNA	23	23	100%	4 <sup>b</sup>	17%
C12-DNA	13	13	100%	3 <sup>b</sup>	23%
C20-DNA	13	13	100%	3 <sup>b</sup>	23%






FIG. 1



4/6




FIG. 2



5/6





FIG. 3





A



B




FIG. 4

Pct/GB97/00074

9600470.0

W/ Thompson & Co

10.1.97